Podcasts about Lynch

The latest episode of the Cambridge Tech Podcast features a fascinating panel discussion on international trade recorded live at this year's Cambridge Wide Open Week.Steven Lynch, Director of International Trade at the British Chambers of Commerce (BCC), opens with a sobering statistic: whilst only 10% of British businesses export, the BCC's network achieves a remarkable 45%. This disparity represents a significant untapped opportunity. As Lynch points out, "If we increased UK exports by 2%, we could improve UK GDP by 0.6%."The problem isn't a lack of innovation or ambition; it's a delivery gap. UK founders and scientists often lack the business expertise and market clarity needed to confidently enter international markets. This is where the new trade accelerator comes in.Rather than offering generic webinars about exporting, the BCC has created something fundamentally different: an end-to-end, process-driven accelerator specifically targeting life sciences companies interested in Singapore.Singapore might not be the obvious first choice for UK startups - the US typically dominates - but it's positioned as a strategic gateway to Southeast Asia. With a population of 6 million, Singapore punches well above its weight as a hub for healthcare innovation and life sciences.Jay Sadanandan, a Singapore life sciences expert, highlights the market's unique advantages:The Health Sciences Authority recently launched a close collaboration with the UK's MHRA, enabling regulatory expediency for innovative technologiesAccess to world-class clinical research infrastructure and patient populationsSingapore's ambitious government vision to solve prevention through treatment across healthcareThe 10 selected companies span pre-seed to Series C stages and focus on areas where UK strength aligns with Singapore opportunity: genomics, molecular diagnostics, advanced therapeutics, and enabling technologies like biologic stabilisation. Importantly, companies aren't required to relocate or abandon UK operations. Instead, they use Singapore as a commercial testbed, a lower-risk environment to validate their business model before scaling across Asia Pacific, the US, or beyond.What's Next?The pilot launches in September 2026, but the ambitions extend far beyond Singapore. Lynch reveals plans to scale to Hong Kong, the Gulf, and other strategic markets. The ultimate goal? Moving from 15 businesses entering one market annually to 15 businesses entering different markets each month.For UK startup founders and investors watching the export opportunity, this episode offers genuine insight into how the next generation of British life sciences companies might achieve global scale, and why Singapore might be the launchpad you haven't considered yet.Listen to the full episode on the Cambridge Tech Podcast to hear the complete discussion, including audience Q&A and practical advice for companies considering international expansion.Headline sponsor Holden Polestar Produced by Cambridge TV #CamTechPod Hosted on Acast. See acast.com/privacy for more information.

In this interview on The Tara Show, host Tara Servatius speaks with South Carolina businessman and conservative political candidate Mark Lynch regarding his decision to enter the Republican special primary for the U.S. Senate seat following the death of Senator Lindsey Graham. Lynch discusses his previous primary challenge against Graham, noting that he invested over $5 million of his own funds while fighting against tens of millions of dollars in establishment spending. Addressing current primary dynamics and recent Emerson polling placing him near the top of the field, Lynch presents himself as a business-oriented outsider, criticizing career politicians, term-limit waivers, and political horse-trading while emphasizing his commitment to conservative principles, anti-surveillance policies, and an "America First" agenda.

Lynch riffs on the compilation album by Foreigner The Platinum Collection from July 1999 (Cold As Ice / Hot Blooded / Juke Box Hero / I Want to Know What Love Is). STAFF PICKS: Rollin' Stoned by Great White — Wayne Steal My Sunshine by LEN— Bruce Blue Monday by Orgy — Rob   ENTERTAINMENT TRACK: Main theme from the animated series SpongeBob Squarepants.   **(NOTE: What the Riff?!? does not own the rights to any of these songs and we neither sell, nor profit from them. We share them so you can learn about them and purchase them for your own collections.)

The race is one of many primary contests across the country pitting the power of incumbency against a call for generational change.

The weekly podcast from The Lynch & Taco Morning Show on 101one WJRR in OrlandoSee omnystudio.com/listener for privacy information.

Treaty Talk | Special | Tom Condon on 2018; the catch, the emotion & 2026 Lynch and Rabbitte #Sport

Chosen by Mike Burton of Genuine Chit-Chat fame, Dune was released in 1984 and was David Lynch's ambitious attempt to bring Frank Herbert's famously dense sci-fi novel to the big screen. Produced by Dino De Laurentiis, the film had a reported budget of around $40 million and was shot largely in Mexico, with huge sets, elaborate costumes, miniature effects, and enough invented terminology to make a cinema audience quietly panic into their popcorn.The cast is absolutely stacked: Kyle MacLachlan, Francesca Annis, Jürgen Prochnow, Patrick Stewart, Max von Sydow, Sean Young, Brad Dourif, Dean Stockwell, and Sting, because apparently space needed a tiny pair of metal pants. On release, the film received mixed reviews and struggled commercially, but over time it became a cult VHS-era oddity: messy, fascinating, visually distinctive, and still discussed decades later by people trying to work out what on Arrakis just happened.Checkout Mike's Genuine Chit-Chat here and Star Wars Chit-Chat here.TRAILER GUY PLOT SYNOPSISIn a universe ruled by emperors, noble houses, secret orders, and one extremely valuable substance, a young heir is pulled into a war for control of the desert planet Arrakis.There are prophecies. There are giant sandworms. There are whispered thoughts, glowing eyes, floating villains, and political schemes so thick you may need a flowchart and a lie down.One family will fall. One boy will rise. And one 1980s sci-fi epic will ask the eternal question: what if Shakespeare, space opera, and a fever dream all shared the same VHS tape?FUN FACTSDavid Lynch turned down the chance to direct Return of the Jedi before taking on Dune.The film was adapted from Frank Herbert's 1965 novel, widely considered one of the most influential science fiction books ever written.The soundtrack was mainly composed by Toto, with Brian Eno contributing the haunting “Prophecy Theme.”The famous “weirding modules” were invented for the movie, replacing some of the novel's more internal and philosophical martial arts concepts.Several longer cuts exist, including a television version credited to “Alan Smithee,” the traditional pseudonym used when a director disowns a project.Lynch has often avoided discussing the film in detail, largely because he did not have final cut.The sandworm effects used miniatures and practical techniques, giving them that distinctive handmade 1980s fantasy look.Sting's Feyd-Rautha became one of the film's most memorable images, thanks partly to a costume that appears to have been designed by someone very confident in the future of underwear.Patrick Stewart's Gurney Halleck charging into battle with a pug remains one of the most gloriously baffling images in all of vintage sci-fi cinema.SUPPORT THE SHOWSupport the Show If you enjoy the show and would like to support us, we have a Patreon ⁠⁠⁠here⁠⁠⁠. If you're listening on Apple Podcasts or Spotify, leaving us a 5-star review (and a short comment) really helps more people discover the show. It's quick, free, and makes a huge difference. Referral links also help out the show if you were going to sign up:⁠⁠⁠NordVPN⁠⁠⁠⁠⁠⁠NordPass⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thevhsstrikesback@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/vhsstrikesback⁠⁠⁠⁠⁠⁠⁠⁠⁠

Following the release of Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric on June 16, 2026, the CGA-IGC Education Committee is pleased to present a special podcast episode exploring several of the key updates.In this episode, host Josie Baker, MS, LGC, speaks with NCCN Guideline Panel chair  Samir Gupta, MD; and members Jennifer Weiss, MD, MS; and Rachel Hodan, MS, CGC about key updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer.Together they discuss expanded multigene panel testing recommendations for individuals with colorectal, gastric, and endometrial cancers, including the Category 2B designation for colorectal and gastric cancers diagnosed at age 50 or older. They also address the evidence behind broader testing, access challenges, and the need for more flexible care pathways.Additional topics include updated EPCAM-associated Lynch syndrome risks, limitations of salpingectomy alone for ovarian cancer risk reduction, the omission of PMS2 from the minimum gastric cancer panel, and the distinction between genetic evaluation and genetic testing for patients with multiple adenomas. The episode also introduces a new section on hereditary esophageal squamous cell carcinoma.

Martin Lynch, father of Grace Lynch, speaks ahead of their appearence before the Oireachtas Justice Committee, to discuss scramblers and public safety.

In this third segment of the third hour, host Charlie James interviews State Senator Lee Bright and businessman Mark Lynch regarding the political shifts following the death of Senator Lindsey Graham. State Senator Lee Bright emphasizes that South Carolina needs a true conservative contest rather than a party coronation, pointing out the absolute irony that the newly scheduled August 11th special federal primary will land on the exact date state lawmakers previously claimed was too expensive to open for redistricting votes. Following Bright, businessman Mark Lynch officially announces his candidacy for the vacant Senate seat on the program. Lynch, who previously secured second place behind Graham in the regular primary on an "America First" platform, shares that he felt obligated to honor his base of conservative grassroots supporters. The hour concludes with Charlie James breaking down the newly fast-tracked special primary timeline, noting that early voting will be compressed into a three-day window ahead of the August vote.

In this segment of the program, host Charlie James checks in with local political figures to discuss the moving parts of the newly created election timeline. State Senator Lee Bright emphasizes that South Carolina needs a true conservative contest rather than a party coronation. Bright highlights the absolute irony that the newly scheduled August 11th special federal primary will land on the exact date state lawmakers previously claimed was too expensive to open for redistricting votes. Following Bright, businessman Mark Lynch joins the program to officially announce his candidacy for the vacant Senate seat. Lynch, who previously secured second place behind Graham in the regular primary on an "America First" platform, shares that he felt obligated to honor his base of conservative grassroots supporters. Full Audio Transcript

In this opening segment of the fourth hour, host Charlie James moderates a series of discussions reflecting the political shifts after Senator Lindsey Graham's passing. State Senator Lee Bright emphasizes that South Carolina needs a true conservative contest rather than a party coronation, pointing out the absolute irony that the newly scheduled August 11th special federal primary will land on the exact date state lawmakers previously claimed was too expensive to open for redistricting votes. Following Bright, businessman Mark Lynch officially announces his candidacy for the vacant Senate seat on the program. Lynch, who previously secured second place behind Graham in the regular primary on an "America First" platform, shares that he felt obligated to honor his base of conservative grassroots supporters. The segment concludes with Charlie James breaking down the newly fast-tracked special primary timeline, noting that early voting will be compressed into a three-day window ahead of the August vote.

David Lynch's Wild at Heart  This week we return to a World of Dreams and the Land of Oz through the dark and chaotic eyes of David Lynch (January 20, 1946 - January 16, 2025). A Homage/Love Letter to the classic MGM masterpiece, Lynch's 1990 Wild at Heart is a pulsating cinematic shotgun blast. The story of young lovers breaking parole and crossing the country to find a future that is never clear, Lynch's dark romantic comedy is unlike anything seen before, but inspiring to cinema for decades after. With allusions to Fleming's 1939 Technicolor Classic, as well as nods to Elvis, Americana, and the great tradition of cinematic road trips, Wild at Heart cannot be adequately described, it can only be experienced. This week Mr. Chavez & I describe our relationship to this film (his history with it and my first viewing nearly a decade ago). We discuss our history (and dismissa - minel) of Lynch followed by the embracing of this great American filmmaker (also mine). With particular attention paid to the over the top brilliance of all involved in front of the camera, including: Nicolas Cage, Laura Dern, Diane Ladd, Harry Dean Stanton, Isabella Rosellini, J.E. Freeman, Calvin Lockhart, Grace Zabriskie, Crispin Glover, and Willem Dafoe. We are thrilled to dive into a great film from an incredible director. Take a listen and let us know what you think. As always, we can be reached at gondoramos@yahoo.com. Our Continued Love & Thanks.  For those of you who would like to donate to this undying labor of love, you can do so with a contribution at https://www.buymeacoffee.com/watchrickramos - Anything and Everything is appreciated, You Cheap Bastards.

Mary-Louise talks to Neil on the back of the death of Jamey Carney at the hands of a man in Killarney.

I'm joined today by Dr. Ben Lynch, DNM — one of the most knowledgeable experts I know on methylation pathways, biochemistry, and how prenatal nutrition shapes a child's lifelong health. Dr. Lynch is the author of *[Dirty Genes](https://www.amazon.com/Dirty-Genes-Breakthrough-Program-Optimize/dp/0062698141)* and founder of [Seeking Health](https://www.seekinghealth.com/), and over the years he has become one of the physicians I turn to most for insight on these critical early developmental windows. In this episode, we go deep on a topic that doesn't get nearly enough attention in conventional obstetrics: the difference between synthetic folic acid and the natural folate forms that developing babies actually need — and what happens when we get it wrong.

The Supreme Court just upheld birthright citizenship, striking down Trump's executive order in a 6-3 ruling that leans directly on a case 130 years in the making. We're re-releasing our deep dive into Wong Kim Ark — the Chinese American son of immigrants who won this exact fight at the Supreme Court in 1898 — because Chief Justice Roberts built this week's decision on Wong's story, by name. In this episode: the history of the 14th Amendment, the Chinese Exclusion Act, Julia Lynch's 1844 citizenship case, and how "subject to the jurisdiction thereof" has been the most contested phrase in American immigration law for over a century. Plus a new opening and closing segment breaking down this week's ruling, the rejected "domicile" argument, and why the fight isn't actually over. Birthright citizenship. The 14th Amendment. American identity. Immigration history. All still unfinished business. Show Notes Episode Summary Originally released in 2025, this episode traces the legal and racial history of birthright citizenship in America — from the Naturalization Act of 1790 through Wong Kim Ark (1898), Lynch v. Clarke (1844), and Trump's January 2025 executive order. This re-release adds new bookend segments covering the Supreme Court's June 30, 2026 ruling in Trump v. Barbara, which upheld birthright citizenship 6-3. What's New in This Re-Release Breakdown of the Supreme Court's ruling and Chief Justice Roberts' majority opinion Why the administration's "domicile" argument failed Fact-check: can Congress end birthright citizenship by passing a law? (No — here's why) What comes next for immigration policy after this ruling Topics Covered The 14th Amendment's Citizenship Clause United States v. Wong Kim Ark (1898) Lynch v. Clarke (1844) The Chinese Exclusion Act and the Naturalization Act of 1790 Dred Scott v. Sandford and its legacy Trump's 2025 executive order on birthright citizenship Trump v. Barbara (2026) Host & Producer: Saadia Khan I Content Writer: Michaela Strauther I Editorial review: Shei Yu I Sound Designer & Editor: Lou Raskin I Immigrantly Theme Music: Simon Hutchinson | Other Music: Epidemic Sound Immigrantly Podcast is an Immigrantly Media Production. For advertising inquiries, contact us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠info@immigrantlypod.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠BOYOT (Belong On Your Own Terms) ⁠⁠⁠⁠⁠⁠is the next step. It's our new app, designed to help you think through identity, culture, ambition, relationships, and the stories we carry with guided reflections, prompts, and frameworks developed over years of conversations on this show. It's thoughtful. It's challenging. And honestly, it's the kind of space many of us wish existed earlier in our lives. If you're ready to go deeper than the podcast, subscribe to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BOYOT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and start the journey. Don't forget to subscribe to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Immigrantly Uninterrupted⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for insightful podcasts. Follow us on social media for updates and behind-the-scenes content. Learn more about your ad choices. Visit megaphone.fm/adchoices

We will be covering the David Lynch masterpiece, Twin Peaks: Fire Walk with Me.   Twin Peaks: Fire Walk with Me was released in 1992 as a prequel / sequel to the original series. It was directed by David Lynch and co-written by Lynch and Robert Engels.   This is part of our other show Welcome to Twin Peaks. You can check out the full show anywhere you find podcasts: https://welcometotwinpeaks.podbean.com/   Follow us on Instagram @welcometotwinpeakspodcast   Thanks for joining us for Welcome to Twin Peaks: Horror Hour with the Hanna's deep-dive Twin Peaks "re-watch" podcast. In this series Hannah ventures into the strange and beautiful world of David Lynch and Mark Frost's Twin Peaks for the very first time, guided by Twin Peaks veteran Matt.  Each week, we cover one to two episodes from the show to unpack the filmmaking, themes, music, mysteries, and all the wonderfully weird moments in between. Along the way, we'll spotlight our “Suspect of the Week,” "Who I Trust With My Coffee," "Notes for Diane," and make predictions for the future of the show.    #podcast #twinpeaks #twinpeakspodcast #davidlynch #horrorpodcast #horrormovies #horrorfilm #scarymovie #scarymovies #scarymoviesbelike #horrortok #horrorhour #behindthescenes #howscary #moviereview #filmreview #morbidpodcast #creepypodcast #filmtok #moviesummary #horrorpodcast #horrormovies #horrorfilm #scarymovie #scarymovies #scarymoviesbelike #horrortok #horrorhour #behindthescenes #howscary #moviereview #filmreview #morbidpodcast #creepypodcast #moviesummary #movieexplained #scary #horror #movie #film #behindthescenes #behindthescene #filming #moviefacts #halloween #filmpodcast #horrorfilmanalysis #filmpodcast #horrorgenre #horrorfilmanalysis #newrelease #horrormoviepodcast #tvreview #tvreviews #tvpodcast  

LOI managers are under the spotlight on this week's show as the lads discuss the news, that BTS exclusively broke earlier today, that Ian Ryan and Athlone Town have parted ways. An interesting DM from a listener opens up a debate on the job security of some of the other bosses in the second tier, while Derry City's latest humilation under Tiernan Lynch is also discussed, can the Candystripes turn their season around in Europe this week? Sponsored by QuinnAv.ie & BAR 1 Betting (18+, gamblingcare.ie)

Julieanne Lynch, mother of Kelly Marie

In this episode of The Artists Podcast, we dive deep into the mind of David Lynch with acclaimed film scholar Todd McGowan — author of The Impossible David Lynch, a provocative exploration of Lynch's cinematic language and the impossible, unconscious core of his films.Lynch occupies a rare space between mainstream visibility and independent cinema authenticity — blending the bizarre and the normal, the dreamlike and the narrative, to create films that defy conventional categorization. Whether you're a filmmaker, cinephile, or lover of the strange, this episode reveals how Lynch thinks — and why his cinema continues to challenge and captivate global audiences.Subscribe  @suchita_filmmaker_podcaster  to stay tuned.#TheArtistsPodcast #DavidLynch #ToddMcGowan #TheImpossibleDavidLynch #FilmTheory #CinemaStudies #IndependentCinema #MainstreamCinema #SurrealCinema #PsychoanalyticFilm #AuteurCinema #FilmScholar #WatchEpisode #YouTubePodcast #FilmDiscussion #Cinephile #MovieTalk #FilmAnalysis

In Episode 156, we enter the unsettling, hypnotic world of David Lynch with acclaimed film scholar Todd McGowan, author of The Impossible David Lynch.Lynch is one of cinema's greatest paradoxes. He worked within Hollywood systems and budgets, yet created films that feel radically independent. From Blue Velvet to Mulholland Drive, from Twin Peaks to Wild at Heart, his cinema resists easy interpretation while remaining deeply watchable.So how did Lynch stay between mainstream cinema and art-house radicality?Todd McGowan unpacks Lynch through Kant, Freud, fantasy theory, and the unconscious — revealing why Lynch's films are not puzzles to solve, but experiences to undergo. We explore whether Lynch was more classical than we assume, how he erased the “wall” between fantasy and reality, and why feeling — not logic — structures his cinema.This episode is essential for filmmakers, theorists, and anyone fascinated by how cinema can disturb, seduce, and transform an audience.⏱️ TIMESTAMPS00:00 Introduction01:28 Kant, Freud & Lynch04:20 Erasing the wall (Blue Velvet)06:57 Staying between mainstream & art film (clip)08:15 His most “mainstream” film – Wild at Heart10:01 Godard & Lynch (clip)11:30 Cinema of feeling vs cinema of reason12:20 On Godard's passing (clip)15:57 Lynch as a traditional Hollywood director? (clip)20:12 Dune — $42 million “disaster”?23:09 Blue Velvet, Wild at Heart, Twin Peaks, Lost Highway29:00 Returning to Kant — the philosophical LynchWatch on YoutubeListen on Spotify/ Apple#TheArtistsPodcast #DavidLynch #ToddMcGowan #TheImpossibleDavidLynch #FilmTheory #CinemaStudies #AuteurCinema #BlueVelvet #TwinPeaks #MulhollandDrive #WildAtHeart #Dune #PsychoanalyticTheory #ArtHouseCinema #FilmPodcast #Cinephile

For decades, investing in high-growth private companies was reserved for venture capital firms and institutional investors. Today, the rapidly evolving secondary market is changing that landscape—creating new opportunities for founders, employees, early investors, and institutions to access liquidity long before an IPO. In this episode, we sit down with Brianne Lynch, a venture and private markets expert whose career spans traditional finance, startups, hedge funds, and venture capital. After beginning her career in relationship management and financial services, Brianne made the leap into the startup world before joining EquityZen, where she has become a leading voice on venture secondaries and private market investing. Having worked across sales, partnerships, strategy, market intelligence, business development, and research, Brianne has had a front-row seat to the explosive growth of the secondary market. Her insights have been featured by CNBC, Bloomberg, The New York Times, and Yahoo Finance, making her one of the industry's most recognized voices on private market liquidity. Whether you're a founder considering liquidity options, an investor exploring venture secondaries, or simply curious about how private markets really work, this conversation provides an inside look at one of the fastest-growing segments of venture capital. In This Episode Brianne's journey from traditional finance to startups and venture secondaries What venture secondaries are—and why they matter Why the secondary market has earned the reputation as the "Wild West" Understanding SPVs, secondary structures, and common industry terminology How companies influence employee and investor liquidity What investors should evaluate before investing in secondary transactions Why so many intermediaries exist in private market transactions How secondary markets impact startup financing and IPO decisions The growing role of Registered Investment Advisors (RIAs) in venture investing Resources for learning more about private markets and venture secondaries Key Takeaways Venture secondaries are transforming how liquidity is created in private markets. Understanding transaction structures is just as important as evaluating the underlying company. Company participation can significantly influence pricing, access, and transaction success. A healthy secondary market can strengthen employee retention and investor alignment. As companies stay private longer, secondary markets are becoming an increasingly important part of the venture capital ecosystem. About Brianne Lynch Brianne Lynch is a venture and private markets professional with experience spanning financial services, startups, hedge funds, and alternative investments. At EquityZen, she has worked across multiple functions including partnerships, strategy, market intelligence, business development, operations, and research, helping educate investors and entrepreneurs about the rapidly evolving venture secondary market. Brianne is also a frequent media contributor, providing commentary on venture capital and private markets for leading financial news organizations. Who Should Listen Startup founders Venture capital investors Angel investors Family offices Employees with startup equity Private market investors Financial advisors Anyone interested in venture capital and alternative investments #Venturecapital #angel #startups #secondaries #VC Disclaimer: The views expressed in this podcast are for informational and educational purposes only. They do not constitute investment, legal, tax, or financial advice, nor do they necessarily reflect the views of Finalis Inc. or Finalis Securities LLC, Member FINRA/SIPC. Any discussion of securities, private investments, or investment strategies is general in nature and should not be relied upon as a recommendation or solicitation to buy or sell any security. Listeners should consult their own professional advisors before making any investment or financial decisions.  

Brendan Lynch, co-head of U.S. equity REIT research at Barclays, discussed data center REITs on the latest REIT Report episode, noting that the sector is rebounding as enterprise AI demand accelerates, leasing pipelines grow, and investors seek more direct exposure.Lynch said the recent Blackstone Digital Infrastructure Trust (NYSE: BXDC) IPO shows “there are investors who are looking for a specific type of exposure,” in the data center sector, notably stabilized assets.Meanwhile, record demand should support revenue growth, margin expansion, and cash flow growth as operators scale, he said. Development yields have improved from 6% to 7% in 2021–2022 to low double digits and, in some cases, the mid-teens, although customers' ability to self-build limits the upside.Power remains a key constraint, Lynch observed, but operators are getting more creative through retrofits, grid solutions, and behind-the-meter options. On regulatory pushback, “a lot of the things that are the cause of NIMBYism, I think, are misunderstandings about how data centers can fit into a given environment," he said.Chapters:  00:00 AI CapEx Runway00:39 Welcome to REIT Report00:58 Data Center REIT Comeback02:39 Leasing Pipelines Growth03:08 Development Yields Shift04:28 Power Constraints Markets05:38 Creative Power Solutions06:06 NIMBY Pushback Regulation07:41 Winners Ecosystem Pricing08:49 Is Now Good Entry09:53 Data Centers in Space10:53 Wrap Up Subscribe

El mercado de las criptomonedas vuelve a situarse en el centro de la actualidad empresarial tras la suspensión de la actividad de Binance en la Unión Europea. La medida supone un importante revés para la plataforma, que cuenta con una amplia base de usuarios en el continente. Aunque no existen cifras oficiales, distintas estimaciones apuntan a que alrededor de 40 millones de europeos utilizan sus servicios, de los cuales unos 500.000 se encuentran en España. Según datos de CryptoQuant, las operaciones realizadas desde Europa representan aproximadamente el 1 % del mercado spot de Binance. La decisión se hace efectiva después de que los reguladores de Grecia retiraran la licencia MiCA de la compañía, el marco regulador que permite operar con criptoactivos dentro de la Unión Europea. Pese a este contratiempo, la empresa asegura que no abandonará el mercado europeo. En declaraciones concedidas a Reuters, Gillian Lynch, directora de Binance para Europa y Reino Unido, afirmó que la compañía continúa trabajando para recuperar su posición en la región. Entre las alternativas que estudia se encuentra renovar la autorización en Grecia o trasladar parte de sus operaciones a otros países con una regulación más favorable para el sector, como Letonia o Irlanda. Ambos destinos ofrecen ventajas fiscales y procesos administrativos más ágiles, factores que podrían facilitar el regreso de la plataforma al mercado comunitario. La retirada de la licencia está relacionada con preocupaciones sobre la prevención del blanqueo de capitales, la complejidad de la estructura internacional de la empresa y una gestión del riesgo considerada insuficiente por los reguladores. No obstante, Binance sostiene que ha reforzado de forma significativa sus mecanismos de control. Lynch explicó que la compañía ha incrementado su inversión en cumplimiento normativo y que actualmente cuenta con cerca de 1.500 empleados dedicados exclusivamente a supervisar estas tareas y garantizar el cumplimiento de las exigencias regulatorias. Los problemas de Binance no se limitan a Europa. En 2023, las autoridades estadounidenses investigaron a la plataforma tras detectar que organizaciones terroristas como Hamás, Estado Islámico y Al Qaeda habían utilizado el servicio para realizar más de un millón de transacciones. Ese mismo año, su fundador y entonces consejero delegado, Changpeng Zhao, aceptó el pago de una multa superior a 4.000 millones de dólares por incumplimientos relacionados con la normativa contra el blanqueo de dinero y la regulación financiera. Además, fue condenado a cuatro meses de prisión, en uno de los casos más relevantes que ha afrontado la industria de los criptoactivos.

On this Monday edition of the program, Z sits down with Browns CB Coach/defensive PGC Brandon Lynch (1:25:13) to discuss the standards he holds his DBs to and more. You'll also play Higher or Lower with the top 100 players in the NFL in 2026 (38:14) and get your Weekend Headlines (55:01). Plus, hear some highlights from Beau's eventful trip to Virginia.See omnystudio.com/listener for privacy information.

The potential applications of AI are endless; there are so many solutions in the marketplace that health care organizations can get "paralyzed," according to Kim Lynch, Founder and CEO at Metis Health Technologies. She advises organizations not to debate endless what to do, but to "try something" with "a bias toward action." Jeffrey Nelson, Enterprise Chief Information Officer at Mosaic Health, similarly says to "try and fail," but "move the ball forward."Of course, nobody advises just throwing money at fancy technologies. In our recent interview at the Navina Ascend user conference, Lynch and Nelson along with Ronen Gordon, MBBS BSc, Vice President of Medical Product at Navina, lay out the real benefits of AI along with lessons learned implementing AI in their organizations.Learn more about Mosaic Health: https://mosaichealth.com/Learn more about Metis Health Technologies: https://www.metishealthtechnologies.com/Learn more about Navina: https://www.navina.ai/Healthcare IT Community: https://www.healthcareittoday.com/

The weekly podcast from The Lynch & Taco Morning Show on 101one WJRR in OrlandoSee omnystudio.com/listener for privacy information.

A 10h, ce jeudi 25 juin 2026, les GG : Flora Ghebali, entrepreneure dans la transition écologique, Charles Consigny, avocat, et Jean-Loup Bonnamy, professeur de philosophie, débattent de : Louis, 17 ans, lynché à mort sur un chantier à Narbonne !

Peter Lynch erzielte von 1977 bis 1990 eine durchschnittliche Jahresrendite von 29,2 %. Dies ist der beste Track Record eines öffentlichen Investmentfonds, in den damals laut Angaben von Lynch jeder hundertste Amerikaner oft mit kleinen Summen investiert war. Was war der größte Anlagefehler von Peter Lynch? Über diesen Anlagefehler sprechen wir heute und wir diskutieren auch, warum es sehr schwierig ist, diesen Fehler komplett zu vermeiden. Wir sprechen auch darüber, warum sich Peter Lynch auf dem Höhepunkt seiner Karriere als Fondsmanager mit 46 Jahren zurückgezogen hat. Veranstaltungsreihe "Die Kunst Unternehmen zu bewerten (aus Investorensicht)": Lerne Unternehmen wie ein Profi zu bewerten Jeden Sonntag mehr Geldbildung direkt in Dein E-Mail-Postfach. Seit 2014. Schließe Dich über 10.000 cleveren Geldbildern an: Jetzt Teil der sonntäglichen Community werden

Alyssa Lynch is a content creator, entrepreneur, and wellness advocate known for her candid conversations around personal growth, relationships, mental health, and living authentically.In this episode, Alyssa opens up about one of the biggest lessons of her life: leaving a relationship she knew wasn't right and finding the courage to trust herself. She shares what being lied to and cheated on taught her, the fear of starting over, and why finding a healthy relationship can sometimes shine a light on the parts of ourselves that still need healing.We also discuss my marriage and divorce, healing in love versus healing alone, Alyssa recovering her period after years of stress and the wrong relationships, navigating histamine intolerance and MCAS, living with chronic health challenges without letting them define you, and the connection between emotional health and physical symptoms.Plus, Alyssa shares the wellness trends she's over, the habits she had to quit when wellness became unhealthy, the beauty treatments she actually thinks are worth it, her favorite skincare products, and the practices that have made the biggest difference for her nervous system.You can find Alyssa at @alyssalynch on Instagram, TikTok, and Substack.This episode is brought to you by:Get 15% off at BON CHARGE by using code BLONDE at www.boncharge.com.Head to Nutrafol.com and use code BLONDE for $10 off your first subscription and free shipping.Head to paleovalley.com/well, or use code well at checkout for 15% off your first purchase.Head to ladder.fit/WELL for a 7-day free trial and $10 off your first month.Get 15% off your sitewide purchase and use code well at drinkspindrift.com. Go to qualialife.com/WELL for 50% off, and use code WELL for an additional 15% off your order.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode.Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers.   In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.  Our host, Sharon Jones is joined by:  Dr Katie Snape, Principal Clinician for Population Health at Genomics England  Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University  Drew Hyde, participant in the Cancer Prevention Programme (CaPP3)  Links:  Listen to: How can genomics help us understand cancer?  "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think."  You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So to start with the basics, Katie, can you walk us through what cancer is in simple terms? [00:00:50] Katie: Sure, Sharon. So, our body is made up of cells. Those are the building blocks that, that make us as humans and other creatures and plants. And our cells need to keep dividing throughout our lifetime as our bodies are growing and working normally. [00:01:06] And so we need to have processes in place in our body where our cells can divide, but then also stop dividing when we don't need them to carry on dividing. What happens in a cancer cell is basically that cell becomes abnormal, and it doesn't follow the normal checks and balances and rules of cell division. [00:01:23] So it starts to divide and grow uncontrollably, and it can start to invade other tissues and obviously, that can cause serious consequences. [00:01:33] Sharon: We'll hear a lot more from Dr. Katie Snape in this episode. But before we move on, I just wanted to flag that there was an episode of our Genomics 101 explainer series with Katie dedicated to helping us get to grips with how genomics can help us understand and diagnose cancer. [00:01:47] Do go and check that out. We'll put a link to that in the episode description. [00:01:54] So the World Health Organization estimates between 30 to 50% of all cancers are preventable. So, Katie, when we talk about cancer being preventable, what does that actually mean? And what's an example of cancer prevention that people might already know? [00:02:11] Katie: Yeah. So some cancers are due to chance or just mistakes happening as our cells copy. [00:02:19] Other cancers are because there has been damage to the genetic information within the cell that can be caused by certain things that can cause damage to DNA. So for example, a sort of obvious answer would be skin cancer. Skin cancers can be caused by sunlight, the, the UV light in the sun, and particularly if we burn our skin or, or get sun damage to our skin, increases the chance of us developing a skin cancer. [00:02:44] So you can think of lots of other examples such as cigarette smoking and lung cancer, and so we know that there are a number of different risk factors that increase the chance of our cells developing damage and becoming abnormal cells and growing uncontrollably. So when we talk about prevention, we might think, well, could we reduce some of those risk factors and therefore reduce the chance of those cells getting damaged and becoming cancer cells? [00:03:10] So I gave the example of skin cancer. We might put sun cream on if we're going out in the midday sun, for example. That reduces the damage of the UV light onto our skin cells. Or we might help people to go into a smoking prevention programme or, you know, other risk factors, such as we know that being very overweight can increase the chance of cancer. [00:03:31] We might help people get into more exercise regimes or improve people's diets. So those are the sorts of things that we might do sort of for environmental risk factors. But we also know, particularly in this context, that sometimes people are born, they carry genetic changes within their cells that they're born with, that are inherited, that run through families, and those can also increase the chance of some cancers developing. [00:03:56] And for those people at higher genetic risk, then we might look to other ways that we might reduce that risk. We can't change the genetic changes in their cells, but we might be able to put things in place to reduce the risk for those individuals, and that might be medication, it might be surgery, or there could be other things that we might be able to offer. [00:04:15] Sharon: Yeah, and with that in mind, is there anything more, you know, that you can share about some of those risk factors that someone is more likely to develop cancer? [00:04:25] Katie: Yeah. So actually, the, the biggest risk factor for developing cancer is age. The older we get, the more times our cells have divided, the more chance there is of a copying mistake that, that, that can cause that cell to become abnormal and start growing uncontrollably. [00:04:41] And that's why cancer becomes more common the older we get. We obviously can't change our aging process. Then, as I've said, sometimes we're born with certain specific inherited factors that increase the risk. That might be one big high-risk genetic factor, such as having a cancer gene that's important for, for that process of cell division that isn't working properly. [00:05:04] Or it could be that we have multiple lower genetic risk factors that can kind of add up together to increase the risk. And those often interplay with some of those environmental factors that we've talked about, like smoking, for example, or weight, or alcohol or other things like that. So most cancers are due to aging, and then there's a sort of interplay of genetic factors, but environmental factors as well. [00:05:30] Sharon: That's really interesting to understand. And the focus of this podcast is sort of looking at kind of Lynch syndrome and what findings have come out around aspirin and having a low dose of aspirin. So I want to kind of explore what Lynch syndrome is and, and then bring in Drew to talk about his experience of having Lynch syndrome and how he got involved in the trials themselves. [00:05:49] So from what I understand, Lynch syndrome is a genetic condition that can make some people more likely to have the chances of developing into bowel cancer. And Drew, this is your opportunity to sort of talk about what that's been like living with Lynch syndrome. And, you know, I'd like to understand more about your story and how it came about that you discovered that you had Lynch syndrome, and to share with our listeners your journey. [00:06:13] Drew: Yep. So in my case, I discovered I had the colon cancer before I discovered I was a Lynch syndrome carrier Basically, at the age of 50, I noticed some change in my health. You know, I was becoming a little bit more tired. My bowel movements had changed or whatever. So, I went to the GP and the GP basically said, "Well, you're probably too young for cancer, so let's look at other alternatives." [00:06:37] And I had blood tests and I had low iron, so I was on iron tablets for three months and whatever. Then eventually I went back and finally the GP said, "Well, let's try a colonoscopy." And the colonoscopy revealed that I did actually have colon cancer. And then very quickly I had surgery and, uh, then following that, I kind of asked the question, "Well, why me?" [00:06:59] You know, I'm only 50, 51. Yeah. You know, why me? [00:07:02] Drew: And basically, I was told, "Well, it's probably genetics." And then I was referred to, you know, St George's and Katie and I had the test and discovered that I was actually a Lynch syndrome carrier, and that's why, you know, I'd got the colon cancer at the age of 50, so. [00:07:17] Sharon: I mean, that's quite a journey. I mean, how did you feel when you're already on one pathway and then having to kind of find out more, you know, what was your experiences? What was the impact on your life? How did you, how did you feel? [00:07:27] Drew: I think I was lucky in that I had a very good surgeon. I had surgery very quickly, so that was the first hurdle. [00:07:32] Then I had to go on to chemotherapy, and the chemotherapy obviously is far worse than any surgery or anything else that comes before or after. But having got through that, then I went through the St George's onto the Lynch syndrome system. So, the most important thing then really was to basically identify what that meant for me, but also because it was an inherited characteristic, what it meant for my family. [00:07:57] One thing that was interesting, and I say, you know, the, the GP was saying, "Well, you're too young to have cancer," is that there wasn't any history of cancer in my family, you know, looking at older relatives. So, you know, to be fair to the GP, that wasn't an obvious marker. So basically, yeah, it was let's, you know, find out what it means now going forward. [00:08:21] Sharon: So, can you just take us back to when you were diagnosed with Lynch syndrome? What sort of guidance were you given at the time about managing your cancer risk? [00:08:30] Drew: Well, following the surgery, I was given various statistics which were fairly grim on what your percentage survival rate were in three years, five years, 10 years based on the surgery, whatever. [00:08:39] And that was kind of a bit harrowing. But, you know, assuming I'd get through five years, I felt it was, my chances were quite good. As for myself living with, living with Lynch syndrome, that, you know, I was aware that having had the colon cancer, I then had increased risk of other cancers. So since then, I've been on a screening programme, and I have colonoscopies or gastroscopies every year or two years. [00:09:04] So that's been very good. So, I believe now that if any other cancers were to appear, I would probably know very early on because they would be detected through a screening process before they got to a point where they would be, you know, maybe too difficult to resolve, so. So that's-- I think the screening programme, has been very, very good. [00:09:23] The main issue for me was what it meant for my family, being a genetic thing. So very quickly, my children, who were teenagers at the time, were both tested, and they went through some counselling with Katie beforehand, you know, about what it would mean for them to get a positive or negative result. [00:09:42] Unfortunately, my daughter was tested as negative, but my son was tested as positive, so he's now on the same cancer screening programme, and has colonoscopies every two years. So yeah. The mystery really, though, is where I inherited it from because my father died when I was very young. My mother was in a care home at the time, and I wanted to get her tested. [00:10:07] And at the time, her GP wouldn't test her on the basis that she was unable to give consent. But fortunately, I had power of attorney, and we could persuade him to do the test. But she tested negative. So I'm assuming I inherited it from my father's side. But most of my grandparents on that side of the family lived into their nineties without any apparent cancers. [00:10:32] So it's still a bit of a mystery how I inherited it, but what was important for me was to know which side of the family I'd inherited it from because obviously with cousins and whatever on different sides of the family, I wanted to be able to tell them what the situation was. My brother also tested negative, which was a positive. [00:10:54] So at the moment, it's just my son and I that have the defective gene. [00:10:59] Sharon: I'm sorry to hear that about your son, but does it- [00:11:01] Drew: Well, well, I mean, he, you know, he has to go through a colonoscopy every couple of years, which, you know, obviously is not a pleasant experience. But at least he knows that, you know, the first sign of any problem, the medics will be aware of it, and he'll be able to react. [00:11:16] Sharon: Has it changed your outlook on life, having this window in possibly knowing stuff or not knowing stuff? How has that affected you and, and your son as well? [00:11:25] Drew: I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So, I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think. [00:11:42] Sharon: Yeah. That is really important. And moving into about the trial more broadly, scientists have known that there's been a link between cancer and aspirin for some time, with fewer cancers observed in people who take aspirin. So coming to you, John, could you share a bit more about the history of inherited cancer research and how the focus of Lynch Syndrome came about? [00:12:02] Because this isn't new, is it? [00:12:06] John: No, absolutely, Sharon. And in fact, this story, my story in this space begins 40 years ago when I was one of the geneticists who set out to try and find the genes that we've just been talking about. At that time, the group of patients who were the most obvious to begin with were young people with a condition called familial adenomatous polyposis, or FAP for short. [00:12:26] And they'd get thousands of polyps in their bowel, and the only way to treat that was to actually remove the whole bowel when they reached adulthood, which is a fairly extreme intervention. And I was running, I was setting up a registry. We were trying to find the gene at that time, and we'd just found it, in fact, but we also were trying to find all the families. [00:12:44] And I'd taken over responsibility for all the genetic services in the north of England, in the North East and Cumbria. And we'd, I'd started identifying families with FAP, and we went to visit one of those families, and this was the kind of light bulb moment for me because I walked into the room and mum had had her colon removed, and her son, Jonathan, had just had his first colonoscopy at the age of 12, and it was clear. [00:13:07] And I was about to give them the good news, but as I walked in, I noticed that he had little bumps on his forehead called osteomas, little bony bumps. His mother had them just the same, and it was one of the features of this condition. So I knew he had the gene even though he hadn't yet got the polyps. [00:13:21] Sharon: Wow. [00:13:22] John: And it made me think, wouldn't it be nice if we could do something to prevent these things happening rather than just waiting for an operation? And as it happened at the time, I was leading the English end of a big study, which you'll probably be aware of, which we're, we're, we were doing the vitamin study on women with spina bifida babies, and we were just about to identify folic acid as a way of preventing spina bifida in pregnant women. [00:13:45] So I had these two thoughts in my head. Maybe we could set up a trial like this folic acid trial, and then one of my friends in Edinburgh said, 'Have you seen this paper from Melbourne?' Gabriel Kuhn had just done a big study looking at people with colon cancer. It seemed that people who took a lot of aspirin didn't seem to get as much bowel cancer in Melbourne as those who didn't. So that was the design set up. [00:14:08] We were applying to Europe for a concerted action, so we had to think of an acronym that began with CA. So I, I came up with Concerted Action Polyp Prevention. But then in 1993, just as we started that trial, we were involved in finding the first of the genes for Lynch syndrome. We had a big family in Northumberland where there were lots of people like Drew's family, and there were three generations of cancer in the family. [00:14:31] So CaPP2 was immediately born in my head. In 1999, we had our first recruit, and we recruited until 2005. We found, in total, 1,000 people in 16 countries to join in, and we gave them two aspirins a day or two dummy tablets. Two aspirins is quite a big dose, but back in my day when I was a junior doctor, we used to give many more tablets of aspirin to people with arthritis. [00:14:57] So two tablets wasn't such a big deal. Nowadays, it's seen as a very high dose. And it worked. Basically, to cut to the chase, when we looked in 2010, the people who were getting the aspirin were getting less bowel cancers. In fact, it was a 50% reduction. So the people who took two aspirins had half as many bowel cancers and fewer cancers of other types as well. [00:15:19] We realised, although, at this point, immediately we saw that it was working, we knew we'd need to do another trial to see whether a smaller dose of aspirin would be just as effective. So CaPP3 began, and the great news is that what we'll be reporting in the journals in the next few days when it gets published, is that the people who were taking  CaPP3 aspirin in any dose were tracking exactly the same as the 600-milligram group in CaPP2. [00:15:46] So we're pretty sure that it works. We're pretty sure that the small dose is just as good. And the great news was that we had fewer side effects in that group. And so in fact, no one had to go to hospital for a transfusion or anything, you know, like that. Whereas in the 600-milligram group, we had a few people who needed treatment because, as you know, and everyone knows, if you take aspirin, there's a higher chance of having an ulcer that causes a bleed. [00:16:10] And that was always the anxiety. But people like Drew were courageous enough to take the chance because they knew we needed to know the answer to this. And of course, when you compare it to the risk of getting cancer, taking an aspirin is a relatively small risk. [00:16:26] Sharon: So, what were your kind of considerations when you were designing the trial, having that knowledge? [00:16:32] John: Well, the first thing is it has to be fully informed consent, which means that you have to explain to people what that risk is. The important thing about aspirin is that doctors have a much worse opinion of it than it deserves because if you work in a hospital, you'll often see people coming in who've had a bleed. [00:16:48] It's not always caused by the aspirin. The thing is, if you're coming with a bleed and you're on aspirin, everyone blames the aspirin. Right. About half of them would've happened anyway. In fact, the, the irritation of the stomach is much more of a problem in older people So in fact, the average age of the people in CaPP2 and CaPP3 was about 45, 46 when they started. [00:17:08] Drew was a little bit older, but, but people in that sort of middle age group are much, much less likely to get into trouble than people in their 70s and 80s. And it's people also who've had a history of ulcers that have a bigger problem. We also knew that if you had a stomach infection called H. Pylori, which is itself a risk factor for cancer, and about one in six people carry that bug, and we knew that if we fixed that with antibiotics, that would significantly reduce the risk of bleeding as well. [00:17:37] So it was a manageable risk. It was something we could share with people. They knew they were taking a bit of a chance. But actually a good way of putting it in terms of the risk, for people in middle age, the risk of a low dose of aspirin is about the same as the risk of having a colonoscopy, which is very small, but it isn't completely without risk. [00:17:56] Sharon: Yeah, and Drew, kind of like hearing this sort of incredible, like, backstory about how we've got to these trials and where we are today What was your experience like as a kind of participant of this trial? [00:18:08] Drew: I understood I was going to be on 100, 300, or 600, but wouldn't know for at least three years, or was it five years? I can't remember. [00:18:15] And then sometime later in the post we got these packs, and it was ... I remember at the time thinking it was like a rather dull advent calendar - ... in that you'd have the days of the week- ... with the little, with the little windows, and you'd, you'd pop the tablets out three times a day and take them. [00:18:31] So I did that. I think, you know, I, I don't think I ever missed a day or whatever. Initially, I thought I must be on a really low dose, because I didn't actually notice any side effects. You know, I remember saying to my wife, I said, "Oh, I think I must be on the lowest dose, because I don't see any side effects." [00:18:46] It was a surprise years later when I was told actually I'd been taking 600, so. [00:18:51] Sharon: Wow. [00:18:52] Drew: It was quite an easy experience really. [00:18:54] John: We had a lot of problems. We had to pack the aspirin in six-month packs, because it was very expensive to pack this stuff up. It cost... We got the aspirin free from the Bayer company, but it cost us more than a million pounds to actually put it in, in the packs to satisfy the regulations. [00:19:10] Uh, and a lot of people complained that the packs were a bit big and awkward, but that was just, you know, a constraint. But it was not that big a deal once people got into it. But we did get a lot of complaints about the size of the packets, which we couldn't do anything about that. [00:19:24] Drew: They came regularly through the post, and, you know, so every three months or whatever I got another supply, and I just carried on taking them. [00:19:30] Yeah, so. [00:19:31] Sharon: What was going through your mind when you were kind of waiting for this potential outcome, Drew? Because you, like you say, it was, you know, it was a long time taking part. What was... Especially as you were opening your, you know, your package a day, knowing exactly what you were going to get. [00:19:44] Drew: Well, I, I kind of knew it would be a long-term thing. [00:19:47] I think I was committed for five years initially. But I carried on taking the aspirin for another probably five years after that. So yeah, I was just sort of happy to take the aspirin and then sort of wait to see what the results would be. As I say, that I didn't really notice any side effects, so I wasn't really worried that it was having any detrimental effect on me. [00:20:09] So I was curious to see what the, what the results would be. [00:20:12] Sharon: Yeah. John, the trial has provided like the evidence that, you know, low-dose aspirin can prevent bowel cancer. But are there any challenges that still exist with translating this research into clinic and ultimately patient care? [00:20:26] John: Well, yes, and I'm going to hand back to Katie, who's actually leading the charge on, on getting it into practice as well. [00:20:32] But just to say that I, I'm actually now literally on my other computer finalising my bid to go back to Cancer Research UK because we want to go for three more years. Wow. We said that we would follow people for 10 years after they'd finished their ... or after they'd started, so, you know, for at least 10 years. [00:20:50] So the last person to join didn't finish until 2024, so we won't get to that person. It's Robin and one of my patients. We won't get to Robin's 10-year anniversary until 2029. Oh, yeah. By which time, obviously, Drew will be even further on. But that will give us at least 10 years of follow-up because we know that there is this delayed effect, and that was seen right back at the beginning when people looked, for example, the nurses study in America, where they followed 86,000 nurses and just asked them if they took aspirin. [00:21:18] And nothing happened for 10 years, but those who were taking aspirin for more than 10 years saw a benefit. So in the general population, it probably takes that long to kick in. And so we need to keep going for just a while longer. It's not as expensive now because we're not giving people aspirin anymore. [00:21:33] Sharon: Yeah. [00:21:34] John: But one of the reasons we g- we made Drew's dose blind was because we wanted to know what the side effects would be when you didn't know how much you were getting There's a danger if you're getting a higher dose, you're more likely to complain. And actually, it did work out that the people on the lowest dose had the fewest side effects, even slight side effects. [00:21:51] The only thing we can't escape from is if you're taking aspirin, you get bruising more easily because it blocks the platelets, which are the little tiny blood cells which plug up little holes in your blood vessels when they leak. The good news is we now know that platelets turn out to be right, a major factor in triggering cancer. [00:22:09] And so the aspirin, by blocking the platelets, is actually reducing the risk of cancer, but also reducing the risk of cancer spreading in the body. So this is new research, and we've got another big research project in collaboration with a team in Cambridge who are, uh, pursuing this. Also, the other exciting news is that my other partner, Ruth Langley, is running a big trial of people with cancer, and those who are given aspirin as part of their treatment have less likelihood of getting spreading cancer later on. [00:22:39] So the aspirin is clearly doing something good at many levels in the system. Surprisingly, and we think it might be partly, partly because we used to have a lot of salicylate in our diet, which is what aspirin's made from. And we think that maybe we're putting back something that the body actually was used to having. [00:22:57] Yeah. But modern diets don't contain any, any salicylate because of the way we prepare our food. So it may well be that a little bit of aspirin's a good thing for everybody, but obviously, that's a choice that each person will have to make. [00:23:09] Sharon: Yeah. I mean, it's a real powerhouse of a, of a drug essentially, which you're finding out more about its benefits as, uh, as research goes on. [00:23:18] So Katie, can you just give us a bit of a broad overview of Genomics England's new adults program, which is kind of looking at this sort of area of work and, and what, how can it benefit people? [00:23:29] Katie: Yeah. Thank you, Sharon. So, the adults programme at Genomics England is being funded by government, and the government wrote about it in the 10-year NHS Health Plan, the Life Science Sector Plan to run a large-scale genomics population study. [00:23:44] So looking at how we can obtain genetic information from people in the population and look at more proactive and preventative healthcare, and can we generate evidence on where, how, and why the NHS should start applying genomics into kind of more population health measures. So, there's sort of two sides to this. [00:24:05] So the first is thinking about pharmacogenomics, which is basically about how genetic factors influence how we respond to drugs. So lots of people have had experiences of having side effects from drugs, we've just been talking about that with aspirin, or for drugs not working so well for them. And we know that there are certain drugs that genetic factors can influence whether you should take the drug at all, or if you do, what dose you should take, whether it's going to work for you or not, whether you might be more likely to get side effects or adverse reactions. [00:24:34] So part of the programme's looking at that. And then the other half of the programme will be looking at sort of is, are the genetic factors relevant for sort of serious and high-risk conditions in the adult population? So we could take bowel cancer as an example of that, a common condition, breast cancer, you know, common cancers or cardiovascular disease. [00:24:58] We know there are certain genetic factors for some people that have significantly increased their chance of developing those serious adult onset conditions. Can we find those people in the population and then put measures in place to prevent that? So, you know, even just thinking about Drew's story, he didn't have a family history of cancer. [00:25:16] The first time that he knew he had Lynch syndrome, he'd already developed bowel cancer. And we know that many people that have Lynch syndrome or other high-risk cancer genes are unaware of their status in the population, and so, um, the idea of this program is to really look at, well, if we were to, to look for some of these very high-risk genes in the general population, could we then put measures in place to reduce the chance of them developing the serious condition as a consequence? [00:25:44] So instead of Drew presenting with his bowel cancer, we'd actually already picked it up, despite the fact he doesn't have a family history, and we'd offered him, let's say, aspirin if we'd known the information at the time, and we could maybe have prevented him from developing bowel cancer. [00:25:58] So it's really exploring looking at that a little bit more. [00:26:02] Where can we get genetic information in the population? Where might there be a really well-evidenced, like all the work John's done over 40 years, is really well-evidenced now. Yeah. Yeah. Where are there these opportunities for us to turn the dial on some of these common adult onset conditions? [00:26:20] Sharon: What other challenges do you think with getting this out there do you see? [00:26:25] Katie: Uh, I think there's, there's lots of challenges. I think it's a really com- ... complex programme of work. The first thing is that the risks might be different for people in a population than have a family history. So where I've worked for, for years, and John as well in, in clinical genetics, we've seen the highest risk people, the people with lots and lots of cancer in their family because they're the people that are presented to healthcare services. So we've worked out the risks based on that population. It will be really different when we move to the population setting. We'll find fewer people, and the risks might be lower because there might be other factors that are giving them a lower risk. But that's not to say the risk is zero. [00:27:05] It's probably still raised. So then what we need to do is we need to consider, okay, well, what can we do to intervene, taking into account this change of context from people that we found through clinical services to people that we see in the population. And aspirin is a great example of this. [00:27:22] So, you know, if we find that someone has a Lynch syndrome gene, then taking aspirin, unless there's a really good reason for them not to take aspirin, is almost certainly going to be low cost to the NHS and really significantly reduce the chance of them developing bowel cancer with a low risk profile. So where are those opportunities? [00:27:41] And that isn't clear cut, and that's why we need a large scale research programme that can try to help the NHS answer some of those questions, so it can decide how best to spend its money in, in the people that are most likely to benefit from it with the least amount of risk or harm to them. [00:27:58] Sharon: That makes sense. And, and so, you know, going to you, Drew, what are your kind of thoughts on some of the challenges that Katie's highlighted? And is there anything else that you think needs to be improved in better supporting people living with inherited risk of cancer in the future? [00:28:14] Drew: In the brief sort of 10, 15 years or whatever since I've been s- suffering, awareness has increased greatly. [00:28:21] I mean, for example, my GP now knows about Lynch syndrome, whereas I don't think she did when I was first diagnosed, and I think there is a little bit more awareness out there, but I still think it's a lot less than there would be for, say, for breast cancer. So for example, when a high-profile personality reveals they've got breast cancer, you often get information about inherited risks. [00:28:44] You don't seem to get that with colon cancer. You know, when it's announced that so-and-so has died or is whatever, you don't get that same, you know, it, it might be a genetic thing. I mean, when I was first told people that I had bowel cancer, the response I got usually was, "Oh, poor diet, was it?" [00:29:04] And I always felt a bit upset, that, you know, actually my diet was fairly healthy. And that was the assumption that people had. So I think anything that gets the message out there that there is a risk, an inherited risk, I'm not sure what the statistics are now, Katie, is it one in 400 people might be a Lynch syndrome carrier or something like that? [00:29:24] You know, it's relatively high for something that is, if you know in advance you're at risk, you can do something about it. But like me, you know, I waited until it was too late, because I didn't know, and then had to have the surgery, so anything that promotes the message that there is a risk. I know some people don't want to know about their genetic makeup. Obviously, that's a choice. But I think to give people, as many people as possible, the choice must be a good thing. [00:29:54] Sharon: Yeah, absolutely. And I think one thing I've noticed through this thread is the sort of theme of funding and what gets funding and the amount of time it takes to, to kind of get that funding. [00:30:05] Is there anything you wanted to add around the kind of funding model, around why some things get funded, you know, uh, more prominent, like Drew's point, obviously, talks about if someone high profile kind of comes forward and says XYZ, that gets the spotlight shone on it, and there might be research going that direction compared to s- to, to other cancers. [00:30:23] John: So maybe I could speak at that. So partly because of my experience, I've now been made chairman of the grant committee at Cancer Research UK for prevention and population research. And there is a real drive to push more resource into prevention for the obvious reasons. [00:30:39] Katie: Yeah. [00:30:39] John: And also, it's got to be remembered, it's very difficult for the drug companies to fund this because it takes such a long time that the drug's- Mm [00:30:46] out of its patent before they actually get to use it. So, it's very difficult from a business point of view to fund research into prevention. But they are keen to help us, uh, but we really need sort of central government and the charities to focus on prevention if it's going to make a difference. [00:31:02] And just on Drew's point on diet, I mean, diet is still important even if you have Lynch syndrome. In our CaPP2 trial, the people who were overweight were more than double the risk of cancer. So it's not like an either/or. If you've got a higher genetic risk and you have a bad diet, then that's, you know, is going to contribute. [00:31:21] But the other exciting thing is, of course, we now have medical ways of treating obesity in, in people. So, one of the interesting areas is whether we should be, in the same way as we are for other high-risk populations with overweight, we should be giving overweight people with Lynch syndrome, help to lose weight because that will also reduce their risk. [00:31:41] It's also worth just dropping in at the last moment here is that this is also a good news story in terms of treatment and further prevention. We now have a new class of drugs called immune checkpoint inhibitors, which specifically target the types of cancer that Drew had and are much more effective in curing them And also, we've just been given funding to do a project called LynchVax, which I'll be helping with, but it's led by David Church in Oxford. [00:32:05] And this is developing a vaccine against cancers in people with Lynch syndrome. The great news is it'll probably work alongside aspirin because we know the aspirin is enhancing the immune response. So the two together may make this a curable condition. [00:32:18] Sharon: That's actually incredible. I mean, that, it gives so much hope for people. [00:32:23] And I just wanted to find out if you had any more kind of reflections as we close, because we're going to come to the end of our podcast today. If there's anything more that you wanted to share, anything that has been missed, or anything that you want our listeners to know, and I think I'm gonna come to you, Drew, first, because you're the person who's had to sort of live through this and, and go through this journey along the way. [00:32:41] Drew: I think just basically, if you're not sure, get tested. Obviously, there are financial constraints. I'm sure that running a DNA test is quite an expensive business. But I think if you've got any history of bowel cancer in the family, you've got any concerns about your health, speak to a GP and see if you can get tested as quickly as possible. [00:33:00] And then, to get a better message out there that there are risks of inherited colon and other similar cancers, so. [00:33:11] Sharon: Yeah, so it's getting that, messaging out, um, for people to understand more and make those informed choices. And Katie? [00:33:18] Katie: I mean, I would say that the power of, of our, you know, NHS and our academia and, and our healthcare system has been collaboration. [00:33:26] Sharon: Yeah. [00:33:27] Katie: There's so many moving parts. There's commissioners, there's funding, there's the evidence, there's research, there's healthcare implementation. The UK's a really amazing place to work in genomic medicine, and I think that's partly because of the amazing collaborations that we have, and the way that we can translate research into healthcare as John's team have done with this amazing study. [00:33:48] So let's all keep working together, please. [00:33:52] Sharon: Absolutely. And John, it feels like this is your lifetime's work. [00:33:58] John: Well, I've become aspirin man, it wasn't intended. But Katie's done fantastic work in her role as chair of the Cancer Genetics Group in the UK, so we've now implemented a, [00:34:06] we're the first in the world to really make this an absolute directive to the GPs and all, to all doctors to say, "People with Lynch syndrome need to be offered aspirin." And so that's a great step forward. But we also need to get it into the British National Formulary, and I'm working with their team so that the GPs are empowered to do this. [00:34:24] It's actually part of their care package. But I would just say we've still got a long way to go. We've now got a national list of all the people with Lynch syndrome, like Drew, to make sure we offer them all a colonoscopy, but there are only 14,000 people after several years of really pushing. [00:34:40] Sharon: Right. [00:34:40] John: We think in the national population in all ages, it's about 1 in 300. That's a lot of people. That means there's about 150,000 people like Drew in the country, and we've only found 10% of them. So we can't just rely on family history for all the reasons Drew explained. You know, I mean, Drew's dad probably died of Lynch syndrome, but we don't know because we've lost that record. [00:35:02] So now we're checking every bowel cancer to see if it might be caused by Lynch, and that programme is now kicking in, and we're picking up a lot more gene carriers as a result of that. But there's still a long way to go to get co- get people aware of Lynch syndrome, to think of it when someone presents with a cancer, not just of the bowel, but in the womb, in the kidney, in other parts of the body. [00:35:23] It's not just the bowel, but that's the most important group. [00:35:26] Sharon: Yeah. [00:35:26] John: So there's still a long way to go. [00:35:28] Sharon: Where you've come to now is still an incredible achievement, even though we've still got a long way to go, and I don't think we should ever lose sight of that. So we're going to wrap it up there. Thank you to our guests, Katie Snape, Professor Sir John Burn, and Drew Hyde, for joining me today as we discuss cancer prevention. [00:35:48] If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app, and thank you for listening. I've been your host, Sharon Jones, and Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Dave Howard at Bespoken Media.  

"That's my own formula — passion and compassion tempered by dedication and humor." This episode is sponsored-in-part by Maddie's Fund, OcuTrap, and Drop Traps: Beginning and Advanced Certification Workshop. After more than five decades behind the exam table, Dr. Kevin Lynch has treated thousands of pets, mentored generations of veterinary staff, and built one of Long Island's longest-running animal hospitals. His new memoir, Off the Leash: Tales From a Lifetime of Healing Pets and Wonder, traces that journey from a 13-year-old kid who talked his way into a part-time job at a local animal hospital to a veterinarian whose guiding philosophy is simple: treating the animal is only half the work, and tending to the person on the other end of the leash is the rest. Dr. Lynch and Stacy dig into one of the thorniest debates in animal welfare: the divide between "indoor-only" advocates and the realities of outdoor and community cat caregiving. Drawing on his own farm-cat memories from working summers on a dairy farm before vet school, he makes the case for listening over judging, and for meeting cat caregivers where they are instead of where a textbook says they should be. From there, the conversation turns practical: how should trappers and community cat program managers actually approach a veterinarian for the first time? Dr. Lynch's answer centers on intention, relationship-building, and showing up with a plan rather than a crisis. The episode also gets personal. Dr. Lynch opens up about compassion fatigue and burnout, a topic he says is as urgent in veterinary medicine today as it's ever been, and shares the daily habits, including a deliberately disciplined relationship with his phone, that keep him from burning out after 51 years in practice. He and Stacy also revisit one of the most harrowing chapters of his career: volunteering with search-and-rescue dogs at Ground Zero after 9/11, an experience he says revealed both the depths of tragedy and the best of human nature. Rounding out the conversation, Dr. Lynch shares a few of the stories from his book, including an unforgettable lesson in slowing down before attempting a DIY tick removal. He also talks about where listeners can find his memoir, his YouTube series The Pet Mindset Show, and the dental care device he invented for dogs and cats. Press Play Now For: How a 13-year-old's unpaid job at a Long Island animal hospital turned into a 51-year veterinary career Dr. Lynch's perspective on the indoor-only versus outdoor/community cat debate, and why he believes there's no one-size-fits-all answer His honest advice for trappers and caregivers on how to approach a veterinarian for the first time Why showing up with "a plan" rather than a crisis is the fastest way to build trust with a vet The role of compassion fatigue and burnout in veterinary medicine, and the daily habits that help him stay in the game His "physical mailbox" approach to managing phone use and protecting mental bandwidth A first-hand account of volunteering with search-and-rescue dogs at Ground Zero after 9/11 The story behind a Rottweiler named Big Shot, and the unexpected humanity he witnessed during that crisis Two unforgettable cat stories from his memoir, including a lesson in patience before attempting DIY pet care Where to find his memoir, his YouTube series, and the dental device he invented for pets Resources & Links Off the Leash: Tales From a Lifetime of Healing Pets and Wonder (Amazon) Dr. Kevin Lynch's website The Pet Mindset Show (YouTube) Plaque Be Gone dental device

In this episode of The Knight Report podcast, hosts Mike Broadbent, Richie O'Leary, and Alec Crouthamel recap the Rutgers Football 7on7 camp, which featured a long list of top prospects. After that, the guys talk about the BBQ visitor list and discuss how that went, along with several other Rutgers musings as the offseason continues. 0:00 – Intro 3:00 – 7-on-7 Tournament Recap: Who Won & How 10:00 – Isaiah Alvarez Dominates for Don Bosco 12:30 – Wide Receiver Commits: Taylor, Alvarez & Mugerwa 17:00 – Other Rutgers Commits on Campus: Glenn, Lynch, Atariwa 22:00 – Big Man Academy Standouts & New Offers 25:00 – KJ Duff: Rock Star Status at Camp 29:00 – Jim Turner: Marine Culture & Karaoke Night 32:30 – Schiano Barbecue Recap & 2028 Class Early Returns 35:30 – NJ Recruiting Hit Rate Deep Dive 46:00 – Official Visit Window Full Recap: All 15 Commits 51:00 – Top Five Commits from the Class Breakdown 63:30 – Nike vs. Adidas: Nebraska Uniform Disaster 70:00 – QB Recruiting: Are They Passing This Cycle? 73:00 – Basketball Recruiting: Marlon Martinez Unofficial Visit 79:30 – Dusty May to the Mavs: College Basketball Carousel Spinning Again Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does it really take to break the cycle of crime? In Part 2 of this conversation, Gary sits down with Lincoln Tarrow-Lynch, a man caught up in crime since he was a kid, who’d spent years dealing drugs, battling ice addiction, and surviving on the fringes of society, to uncover what finally turned his life around. Lincoln opens up about his first adult prison sentence, losing his mother while behind bars, and walking out of jail with nothing but a plastic bag and no support network. He shares how Rainbow Lodge, a post-release residential program in Sydney, gave him the soft landing he needed, and why without it, he's certain he'd have gone straight back into jail. Subscribe to our new Youtube channel. Follow I Catch Killers:Instagram: @icatchkillersTiktok: @icatchkillerspodcastFacebook: @icatchkillersSee omnystudio.com/listener for privacy information.

What happens when the system meant to protect a child chooses to punish them instead? Lincoln Tarrow-Lynch's earliest memory is watching his father being arrested. By five, his mother was in prison. By twelve, he was committing petty crime, living on the streets, and being abused by adults, yet the system kept sending him back to the danger it knew was there. In this episode of I Catch Killers, Gary sits down with Lincoln to trace the fault lines of a childhood shaped by neglect, abuse, and a justice system that criminalised a child who simply needed care. Lincoln's story challenges everything we think we know about youth crime. This episode contains references to child sex abuse and suicide. If you’re experiencing emotional distress, contact Lifeline on 13 11 14 anytime for crisis support and suicide prevention services. If you’ve been impacted by domestic, family or sexual violence, contact 1800 RESPECT on 1800 737 732 anytime for confidential information, counselling and support services. Subscribe to our new Youtube channel. Follow I Catch Killers:Instagram: @icatchkillersTiktok: @icatchkillerspodcastFacebook: @icatchkillersSee omnystudio.com/listener for privacy information.

Operational Civic Leadership: Public Service, Transparency, and Grassroots Strategy with Ebie LynchIn a recent episode of The Thoughtful Entrepreneur Podcast, host Josh Elledge sat down with Ebie Lynch, a candidate running for California Lieutenant Governor under the platform of Ebie Lynch for California, to explore the structural friction points currently stalling civic efficiency and community wellbeing. Ebie, a 24-year Air Force veteran and former specialized prison nurse, brings an analytical, mission-first perspective to public governance, dismantling the gridlocked partisan rhetoric that often alienates everyday citizens. This conversation delivers an intentional operational framework for enterprise leaders, community advocates, and civic minded professionals who are looking to eliminate regulatory debt, foster absolute budgetary transparency, and apply disciplined grassroots strategy to solve the compounding cost-of-living crises facing local economies.Civic Infrastructure: Driving Economic Resilience and Accountability through Mission-First GovernanceThe primary bottleneck dragging down regional economic vitality is the systemic accumulation of excessive regulatory red tape and unexamined public overhead. Ebie Lynch argues that when a government structure operates without clear internal accountability, it naturally introduces friction into local business pipelines, forcing small-to-mid-sized enterprises to pass administrative costs directly down to working-class consumers. True structural scalability within a civic ecosystem is achieved by simplifying licensing procedures, establishing "one-stop-shop" permitting systems, and mapping public tax spending to empirical data tracking models. By treating government spending as a strict corporate balance sheet that demands clear reporting, leadership can cut through waste, ease unnecessary tax debt, and allow regional businesses to retain the capital necessary to drive predictable market expansion and lower everyday cost burdens.Transitioning public healthcare and food logistics into self-sustaining, cost-effective engines requires a top-down commitment to preventative design and localized supply chain optimization. Many institutional frameworks make the expensive mistake of treating downstream illnesses with hyper-reactive, high-cost medical interventions rather than designing proactive, preventative community infrastructure. Real systemic optimization is unlocked when executive leadership builds cross-functional partnerships between regional healthcare providers and local agricultural producers, leveraging California's vast resource abundance to deliver fresh produce directly into localized distribution points. Shifting corporate and community wellness programs toward this preventative, thesis-driven approach significantly mitigates out-of-pocket operational costs, ensuring that health infrastructure protects human capital rather than bleeding corporate or civic margins.Furthermore, building an authoritative and resilient movement in a highly competitive arena demands a disciplined approach to grassroots media and authentic narrative design. When an independent cause or emerging enterprise lacks access to massive institutional capital, it must bypass traditional gatekeepers by leveraging organic digital channels, word-of-mouth networks, and consistent thought leadership. Maintaining strict emotional discipline and civility in the face of marketplace noise or digital setbacks serves as a critical differentiator that positions an enterprise or a leader as a steady, trusted authority figure. When operational precision, radical transparency, and human-centric audience engagement are synthesized under a unified strategy, a grassroots initiative successfully maximizes its reach. This structured model transforms individual participation from an ad-hoc choice into a powerful, collaborative force capable of multiplying long-term institutional value.About Ebie LynchEbie Lynch is a decorated United States Air Force veteran, a former specialized prison nurse, and a dedicated civic candidate running for California Lieutenant Governor. Drawing from more than two decades of rigorous military logistics management and clinical healthcare oversight, Ebie infuses a high-accountability, people-first philosophy into public policy. She is an independent strategic advisor and grassroots advocate focused on helping communities eliminate administrative bottlenecks, improve public health access, and implement sustainable economic reforms.About Ebie Lynch for CaliforniaEbie Lynch for California is the central digital hub and campaign infrastructure platform backing Ebie Lynch's run for Lieutenant Governor. The platform provides voters, business owners, and local advocates with direct access to data-driven policy whitepapers, community permitting reform proposals, and transparent public budgeting frameworks. Through structured volunteer action plans and clear educational outreach, Ebie Lynch for California enables citizens to participate directly in scaling civic transparency and reviving local economies.Links Mentioned in This EpisodeEbie Lynch for California Campaign Website: ebielynchforcalifornia.comKey Episode HighlightsThe Mission-First Leadership Model: Applying 24 years of disciplined military systems engineering to streamline complex public governance pipelines.Eradicating Regulatory Debt: Strategic frameworks to simplify local business permitting and licensing to stimulate grassroots market growth.The Preventative Healthcare Shift: Constructing cross-functional supply loops between local agriculture and health networks to lower out-of-pocket medical overhead.Absolute Budgetary Transparency: Utilizing strict, data-driven non-financial audits to report exactly how public capital is distributed.The Grassroots Authority Blueprint: Overcoming institutional funding barriers by leveraging digital media and human-centric storytelling to scale a movement.ConclusionThe conversation with Ebie Lynch reinforces that true organizational optimization—whether in a corporate enterprise or a public entity—requires a balanced synthesis of structural discipline and transparent accountability. By standardizing internal performance metrics, removing process friction from the frontline, and protecting long-term foundational value, leaders can transform a volatile environment into a streamlined, high-performance asset.More from The Thoughtful Entrepreneur

Charles Schwab's Adam Lynch says Bitcoin's recent decline reflects a classic bear market following a short-lived relief rally, with the FOMC adding pressure to digital assets. He notes investors are rotating into equities like Micron (MU), highlighting a divergence between crypto and traditional markets. Lynch also flags Illinois' new transaction-based crypto tax as a potential headwind that could push firms out of the state.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

This is the weekly podcast from The Lynch & Taco Morning Show on 101one WJRR in OrlandoSee omnystudio.com/listener for privacy information.

PJ talks to Siobhan Lynch whose daughter was killed by a scrambler bike and says that Grace's Law banning the machines on roads needs pursuit training and some reforms to the legal system to work Hosted on Acast. See acast.com/privacy for more information.

In this episode, we are speaking with Bob Lynch, or as the world knows him, the Cowboy Cat Wrangler! Bob is a cat colony carer and TNR advocate for over 100 colony cats in the Philadelphia area. And what that means is ultimately he is rescuing, fostering, vetting, TNR advocating (trap/neuter/return) for every colony he takes care of. He is also a huge advocate and educator about and for cat colonies. Bob is dedicating his life and livelihood to keeping cats-living outside-safe, fed, and as healthy as he can.If you ever want to get down to the heart and soul of animal rescue, then speak with someone who is doing cat rescue and TNR work. It is not for the faint of heart.Next time you see a cat living outside, please think of this episode. It's a really tough life for them, and they need our care and support. And if you don't know what to do, contact us!Thanks so much for listening, and lots of love. Episode Time Stamps:Introduction: 00:16Interview: 8:05Show Notes:Bob's short film about feral cats in Philly, titled Feral Cats in Philly: This Cowboy Takes Care of Them. https://youtu.be/jLi_V54boPU?si=mC9j9nT9k70nDzyX

We're taking your listener questions on this week's episode, including several about one of our favorite directors! Plus, wrestlers acting, Doctor Who, Mark Waid's Captain America, and more!We make our show on Zencastr, and you can too! Follow this link to sign up now!Join the WRA Patreon to help us keep doing the show and get rewards!

We're taking your listener questions on this week's episode, including several about one of our favorite directors! Plus, wrestlers acting, Doctor Who, Mark Waid's Captain America, and more! Learn more about your ad choices. Visit megaphone.fm/adchoices

Giants Defensive Backs Coach, Addison Lynch, tells us what drew him to coaching in the NFL, why communication is so important in the defensive backfield, and what he likes about the Giants defensive backs group going into the 2026 season.See omnystudio.com/listener for privacy information.

Father Lynch speaks of his time missioning at the Lakota reservation. He reflects on how in the second poorest county in the US, he sees spiritual and lifelong change and how much of an impact the Jesuit mission makes in their lives.

Send us comments, suggestions and ideas here! In this week's episode we grab our “They Live” glasses and descend down into Kane Parson's summer blockbuster horror hit: “The Backrooms” to explore its clever symbolic use of Jungian archetypes and Eastern mysticism to create a cerebral and spooky allegory with the same narrative depth we find in masterpieces like Kubrick's The Shining, Lynch's Twin Peaks or Owaku's Silent Hill 2 but with a retrowave drip that weaponizes nostalgia in a tour of the collective unconscious with obscure doorways straight into Buddhist hell. In the free side of the show we discuss Clark and the symbolism that haunts him, the Backrooms and his shadow; breaking down what it has to do with the infinite, changing and cyclical nature of the Backrooms itself. In the extended side of the show we discuss the Capn Carl, Tarot symbolism, the shadow of the retrowave aesthetic and how the Backrooms are a perfect allegory for the Bardos of the Tibetan Book of the Dead. Join us next week for part 2. That gives you a whole other week to go watch the movie before listening! Thank you and enjoy the show!In this week's episode we discuss:Origins of the BackroomsClark Character AnalysisWater Symbolism The Helm and the Wheel of KarmaSamsara, Maya and DukkhaThe Biology of Memory and RepetitionBird symbolismCarl Jung's Psychological ShadowIn the extended episode available at www.patreon.com/TheWholeRabbit we go deeper down the rabbit hole to discuss:Black Mirrors Descending Into the UnconsciousWeaponizing Nostalgia and the Retrowave AestheticTarot: Two of SwordsGematriaDavey Jones LockerMary and the WindowNavigating the Bardos This episode was written by Tim Hacker, Mari Sama and Luke Madrid with additional commentaries by Heka Astra. Where to find The Whole Rabbit:Spotify: https://open.spotify.com/show/0AnJZhmPzaby04afmEWOAVInstagram: https://www.instagram.com/the_whole_rabbitTwitter: https://twitter.com/1WholeRabbitOrder Stickers: https://www.stickermule.com/thewholerabbitOther Merchandise: https://thewholerabbit.myspreadshop.com/Music By Spirit Travel Plaza:https://open.spotify.com/artist/30dW3WB1sYofnow7y3V0YoSupport the show

These witnesses need no introduction... Don Lynch is a renowned author and historian, Ken Marschall is the celebrated artist and Titanic visual historian... together they assisted James Cameron on his 1997 film, they dove to Titanic on multiple expeditions, and they brought us the must-have book "Titanic: An Illustrated History."This live testimony was recorded during our four-day Titanic Anniversary Weekend onboard the RMS Queen Mary. Join us in 2027!VISIT the Witness Titanic Instagram for Episode VisualsorWATCH this Episode on YouTubeNOTICE:Witness testimony begins at 9:05, however for important context, do not skip past 6:35.Episode cover photograph taken by Merie W. Wallace.Big thanks to Ken for providing his paintings and photos to appear in the YouTube version of this episode.Thanks to Sergey Kudriashov for providing us with a few of his photos from the 2001 expedition.Thanks to Maxim Polishchuk for his assistance in getting these photos to our inquiry.And thanks to Paul Carganilla for co-hosting the anniversary weekend with me and making this episode possible!----------------------------------------------Welcome to WITNESS TITANIC — the podcast “inquiry” where we call witnesses of Titanic's great story, from modern experts to even the survivors of the sinking. Through their testimony, we navigate the uncertain waters of the Titanic legend, uncover what actually happened in April of 1912, and ultimately witness Titanic ourselves.This podcast is made possible by the generous support of the Witness Titanic Patrons, and is produced and hosted by Titanic researcher James Penca.LISTEN:Apple PodcastsSpotifyWATCH:⁨YouTube | @TitanicHG⁩Instagram | @WitnessTitanicPodTikTok | @WitnessTitanicPodJOIN THE INQUIRY:PatreonMusic recorded by Ege M. Erdogan | @egecomposerContact | witnesstitanic@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Hey! Nilay here. It's conference season, so I'm traveling across the country and around the world a lot more than usual. Stay tuned for some very special Decoder episodes we have coming up soon, starting on Monday.  In the meantime, I wanted to share a conversation between my friend Peter Kafka and Condé Nast CEO Roger Lynch on the excellent Channels podcast. Lynch says he's told his teams to assume that traffic will be zero from now on — that's what I've been calling Google Zero. Roger also shares his thoughts on AI, the growing influence of the creator economy, and more. Links:  Channels with Peter Kafka | Apple Podcasts Condé Nast CEO: Plan As If Search Traffic Will Be Zero | Search Engine Journal Sundar Pichai on AI, the future of search, and what's happening to the web | Decoder Google Zero is here — now what? | Decoder Google admits the open web is in ‘rapid decline' | The Verge Credits: Decoder is a production of The Verge and part of the Vox Media Podcast Network. Decoder is produced by Kate Cox and Nick Statt and edited by Ursa Wright. Our editorial director is Kevin McShane.  The Decoder music is by Breakmaster Cylinder. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Edward Ryan is the director of global infectious diseases at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.T. Ryan, F. Qadri, and J.A. Lynch. Global Cholera-Control Efforts — Progress and Remaining Challenges. N Engl J Med 2026;394:2177-2180.

Tyler Anbinder traces the migration of Irish families beyond New York City. The Lynch family, for instance, saved money for a decade before moving to Minnesota to establish farms on affordable government land, creating vibrant Irishenclaves in the wilderness. In the West, Irish immigrant Edmund Butler became a prominent military figure, leading troops against Crazy Horse after the Battle of Little Bighorn. In California, the Ruddick family moved from gold mining into real estate, eventually becoming successful landlords. These stories emphasize the resourcefulness of the famine Irish, who repeatedly adapted and started new businesses when faced with failure. (7)1863 DRAFT RIOTS